Don't Crown the Hepatitis C Drug Winner Just Yet

Put that order for a hepatitis C crown for Gilead Sciences (NASDAQ: GILD  ) on hold. Competitor AbbVie (NYSE: ABBV  ) looks like it can give Gilead a run for its money.

In its first phase 3 trial, 96% of patients taking AbbVie's five-drug combo -- ABT-333, ribavirin, ABT-450, ritonavir, and ABT-267 -- were virus-free 12 weeks after finishing the medication. Essentially, the drug combination cured almost all the patients.

The trial enrolled patients infected with genotype 1 hepatitis C virus, the most common in the U.S. Within that genotype, there are two subtypes, 1a and 1b, and the drug combo did quite well on the harder-to-treat genotype 1a, scoring a cure rate of 95%.

More to come
This is just the first in a six-trial phase 3 program. AbbVie is also testing patients that already failed a previous treatment containing Roche's Pegasys or Merck's (NYSE: MRK  ) Pegintron. Vertex Pharmaceuticals' (NASDAQ: VRTX  ) Incivek, the first-generation oral drug that has to be combined with Pegasys, grabbed some of those treatment-experienced patients -- that's part of the reason Vertex had such a successful launch -- but there are still an awfully large number of them considering that Roche's and Merck's drugs were the only thing available for a long time and they only cured about half of the patients that took the drugs.

AbbVie is also testing a five-drug combination that skips the ribavirin. The generic drug can cause birth defects, so leaving it out would be an advantage if it doesn't lower the cure rate substantially. The company expects the trials to read out in the coming months, putting it on target to file marketing applications in the second quarter of next year.

Picking a winner
We'll have to wait for Gilead's phase 3 trials for its all-oral combination in genotype 1 patients to know which drug cures patients the best. When you're comparing the two, make sure it's an apples-to-apples comparison. Genotype, including the subtype, and whether the patient has failed a previous treatment affect how easy it is to treat patients.

Ultimately, though, the competition between AbbVie and Gilead is likely to end up being less about the cure rate than the other factors. If one combination beats the other by a couple of percentage points, I doubt that's going to sway doctors much. The difference might not even be meaningful since the breakdown of the populations in trials might be different.

With comparable efficacy, doctors' and patients' preference is likely to come down to side effects, cost, and convenience, likely in that order. So far, AbbVie's safety profile looks good; if Gilead can match it, the battle might come down to price. Part of AbbVie's regimen has to be taken twice a day while other drugs have to be taken three times a day, so AbbVie may lose on the convenience factor if it comes down to that.

The biggest winner might be Enanta Pharmaceuticals (NASDAQ: ENTA  ) , which helped develop ABT-450 and is due up to $195 million in regulatory milestones, as well as double-digit royalties on sales of ABT-450. If AbbVie can make ABT-450 a blockbuster, Enanta Pharmaceuticals will benefit substantially considering it doesn't have any costs associated with the developing or selling the drug.

Another growth stock with room to run
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2733199, ~/Articles/ArticleHandler.aspx, 10/31/2014 8:37:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement